Chas Bountra, PhD
Home
About Us
Structure
Current Events
Past Events
Video Gallery
Policy & Reports
Awards
Media Coverage
Internship/Volunteers
Legal
Contact Us
 
 
Chas Bountra, PhD
Chief Scientist
Structural Genomics Consortium Oxford
Professor of Translational Medicine
University of Oxford

Chas Bountra is Chief Scientist, Structural Genomics Consortium Oxford and Professor of Translational Medicine, University of Oxford. He was previously Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.

His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and  in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.

He is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

© 2007 - USA India Chamber of Commerce Home | About us | Policy | Events | Photo Gallery | Awards | Media Coverage | Legal | Contact us